It is designed specifically to assess whether the SGLT2 inhibitor dapagliflozin regresses left ventricular [LV] mass in patients with diabetes and left ventricular hypertrophy [LVH]. This evidence concerns the gene SLC5A2 and left ventricular hypertrophy.